Last reviewed · How we verify

National Istitute For Health and Welfare, Finland — Portfolio Competitive Intelligence Brief

National Istitute For Health and Welfare, Finland pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Two policies of iron prophylaxis Two policies of iron prophylaxis marketed Mineral supplement / Nutritional agent Hematology / Preventive Medicine / Public Health

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for National Istitute For Health and Welfare, Finland:

Cite this brief

Drug Landscape (2026). National Istitute For Health and Welfare, Finland — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/national-istitute-for-health-and-welfare-finland. Accessed 2026-05-18.

Related